94 related articles for article (PubMed ID: 11383212)
41. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
Fennelly D; Aghajanian C; Shapiro F; O'Flaherty C; McKenzie M; O'Connor C; Tong W; Norton L; Spriggs D
J Clin Oncol; 1997 Jan; 15(1):187-92. PubMed ID: 8996141
[TBL] [Abstract][Full Text] [Related]
42. [Cyclic high dose CAP therapy by short-stay admission for ovarian malignancies--to increase total dose of CDDP and to improve quality of life of patients].
Ochiai K; Isonishi S; Kimura E; Yokoyama S; Sasaki H; Arihiro T; Terashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jan; 43(1):19-25. PubMed ID: 1997612
[TBL] [Abstract][Full Text] [Related]
43. Treatment of recurrent Kaposi's sarcoma of an AIDS patient with weekly paclitaxel.
Hsu CH; Chen MY; Cheng AL
Anticancer Res; 2000; 20(2B):1159-61. PubMed ID: 10810414
[TBL] [Abstract][Full Text] [Related]
44. Taxol: initial Israeli experience with a novel anticancer agent.
Sulkes A; Beller U; Peretz T; Shacter J; Hornreich G; McDaniel C; Winograd B
Isr J Med Sci; 1994 Jan; 30(1):70-8. PubMed ID: 7908013
[TBL] [Abstract][Full Text] [Related]
45. [A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin].
Shimoya K; Kunishige I; Okuno Y; Hayashi S; Komura H; Arimoto Y; Otsuki Y
Gan To Kagaku Ryoho; 2001 Jun; 28(6):845-8. PubMed ID: 11432356
[TBL] [Abstract][Full Text] [Related]
46. [Treatment of advanced ovarian cancer with cis-dichlorodiammine platinum (CDDP) as single agent or cddp in combination with adriamycin (ADM)].
Nishimura H; Yamada T; Hagio Y; Inoue T; Tsunawaki A; Yakushiji M; Kato T
Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 1):938-43. PubMed ID: 6683483
[TBL] [Abstract][Full Text] [Related]
47. A phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovary.
Reed E; Sarosy G; Kohn E; Christian M; Link CJ; Goldspiel B; Davis P; Jacob J; Maher M
Gynecol Oncol; 1996 Jun; 61(3):349-53. PubMed ID: 8641614
[TBL] [Abstract][Full Text] [Related]
48. [Usefulness of clinical study of irinotecan and cisplatin for recurrent ovarian cancer].
Yahagi N; Kobayashi Y; Ohara T; Kondo H; Suzuki N; Kiguchi K; Ishizuka B
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2583-6. PubMed ID: 20009459
[TBL] [Abstract][Full Text] [Related]
49. [New regimens for the treatment of gynecologic cancers].
Sugiyama T; Ushijima K; Kamura T
Gan To Kagaku Ryoho; 2000 Mar; 27(3):375-81. PubMed ID: 10740630
[TBL] [Abstract][Full Text] [Related]
50. 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer.
Ishikawa H; Nakanishi T; Nawa A; Suzuki Y; Kuzuya K
Int J Clin Oncol; 2001 Jun; 6(3):128-31. PubMed ID: 11706781
[TBL] [Abstract][Full Text] [Related]
51. [Local injection of cisplatin for vaginal stump recurrence of gynecological malignant tumor].
Sato Y; Igarashi S; Kushima T; Tanaka T
Gan To Kagaku Ryoho; 1998 Feb; 25(3):409-12. PubMed ID: 9492836
[TBL] [Abstract][Full Text] [Related]
52. [Prolonged use of paclitaxel for platinum-refractory ovarian cancer--brief report].
Tanaka H; Konishi Y; Saito H
Gan To Kagaku Ryoho; 2001 Mar; 28(3):403-5. PubMed ID: 11265414
[TBL] [Abstract][Full Text] [Related]
53. Weekly 1 hour paclitaxel infusion in patients with recurrent gynecological tumors: a pilot study.
Ota S; Sugiyama T; Komai K; Hirai N; Kumagai S; Ushijima K; Nishida T; Kamura T
Jpn J Clin Oncol; 2001 Aug; 31(8):395-8. PubMed ID: 11574633
[TBL] [Abstract][Full Text] [Related]
54. [Second instance chemotherapy with high-dose cisplatin in patients with advanced ovarian neoplasms in progression or recurrence after treatment with cisplatin].
Bruzzone M; Conte PF; Chiara S; Sertoli MR; Rosso R; Ragni N; Foglia G; Conio A; Pescetto G
G Ital Chemioter; 1985; 32(1):63-6. PubMed ID: 3830794
[No Abstract] [Full Text] [Related]
55. Paclitaxel (Taxol) monotherapy in the treatment of progressive and recurrent ovarian carcinoma after platinum-based chemotherapy.
Blom R; Palm N; Simonsen E
Acta Oncol; 1996; 35(6):733-6. PubMed ID: 8938222
[TBL] [Abstract][Full Text] [Related]
56. Weekly paclitaxel in the treatment of recurrent ovarian cancer.
Baird RD; Tan DS; Kaye SB
Nat Rev Clin Oncol; 2010 Oct; 7(10):575-82. PubMed ID: 20683437
[TBL] [Abstract][Full Text] [Related]
57. [The hypertensive effect induced with angiotensin II and the physiological and pharmacokinetic aspects of two-route chemotherapy using CDDP and STS].
Takizawa K; Harada M; Fujimaru J; Shima Y; Yokoo I; Ozaki I; Sato M; Iguchi T; Takeda Y
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 2):1569-74. PubMed ID: 2389950
[TBL] [Abstract][Full Text] [Related]
58. [Evaluation of a new anti-cancer drug regimen for endometrial cancer].
Fushiki H; Hidaka T; Hori S; Fujimura M; Yamakawa Y; Izumi R
Gan To Kagaku Ryoho; 1998 Jan; 25(1):75-8. PubMed ID: 9464332
[TBL] [Abstract][Full Text] [Related]
59. [Paclitaxel for treatment of colorectal cancer].
Ushigome T; Kawahara S; Hirai K
Nihon Rinsho; 2003 Sep; 61 Suppl 7():338-40. PubMed ID: 14574907
[No Abstract] [Full Text] [Related]
60. [High-dose CDDP therapy using a balloon-occluded arterial infusion (BOAI) in recurrent ovarian cancer].
Suzumori K; Yasui Y; Yagami Y; Mimura M; Banno T; Nakamura T
Gan No Rinsho; 1988 Aug; 34(9):1107-14. PubMed ID: 3172517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
